Almeida R S, Elliott M J, Robinson P J, Wyse R K, Taylor J F, Stark J, de Leval M R
Thoracic Unit, Hospital for Sick Children, London, England.
J Cardiovasc Surg (Torino). 1988 Jan-Feb;29(1):95-9.
The surgical management of congenital mitral valve (MV) anomalies remains controversial and complex. Valve repair has been said to be preferable to valve replacement. To assess the validity of this suggestion we have reviewed our experience of these procedures at The Hospital for Sick Children, Great Ormond Street, London from 1969-1983. In that time 48 patients have undergone surgery; in 23 repair was practicable (Group A) and in 25 replacement of the MV was required (Group B). Group A patients were slightly older than group B patients (5.9 +/- 1.0 years (SEM) vs 3.6 +/- 0.5 years). Björk Shiley valves were the predominant prosthesis used. Overall mortality was 33%, with 17% in Group A and 48% in Group B. Hospital mortality was 4.5% in Group A and 28% in Group B. Actuarial survival for Group A was 90% at 1 year, and 75% at 2 and 5 years; for Group B it was 52% at 1 and 2 years and 42% at 5 years. Mortality was significantly higher in those aged less than 5 years. Four patients in Group A have required re-operation, in 3 valve replacement was required; 2 of these died in hospital. One patient in Group B has required reoperation for valve-related thromboembolism. Three patients are awaiting replacement of calcified bioprostheses. These data support the concept that repair of MV should be performed where possible. The severity of the anomalies was greater in Group B and a rethink as to whether valve replacement is the best option for severe mitral stenosis in those aged less than 5 years seems indicated, in view of the very high mortality.
先天性二尖瓣(MV)异常的手术治疗仍存在争议且较为复杂。据说瓣膜修复优于瓣膜置换。为评估这一建议的有效性,我们回顾了1969年至1983年在伦敦大奥蒙德街儿童医院进行这些手术的经验。在此期间,48例患者接受了手术;其中23例可行修复(A组),25例需要置换MV(B组)。A组患者比B组患者年龄稍大(5.9±1.0岁(标准误)对3.6±0.5岁)。Björk Shiley瓣膜是主要使用的人工瓣膜。总体死亡率为33%,A组为17%,B组为48%。A组医院死亡率为4.5%,B组为28%。A组1年的精算生存率为90%,2年和5年为75%;B组1年和2年为52%,5年为42%。5岁以下患者的死亡率明显更高。A组有4例患者需要再次手术,其中3例需要置换瓣膜;其中2例在医院死亡。B组有1例患者因瓣膜相关血栓栓塞需要再次手术。3例患者正在等待置换钙化生物瓣膜。这些数据支持在可能的情况下应进行MV修复的观点。B组异常的严重程度更高,鉴于死亡率极高,对于5岁以下严重二尖瓣狭窄患者,是否将瓣膜置换作为最佳选择似乎需要重新考虑。